Literature DB >> 9636512

Factors affecting the pharmacokinetics of tacrolimus in the first year after renal transplantation. European Tacrolimus Multicentre Renal Study Group.

N A Undre1, A Schäfer.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9636512     DOI: 10.1016/s0041-1345(98)00234-6

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


× No keyword cloud information.
  30 in total

1.  Evaluation of limited sampling methods for estimation of tacrolimus exposure in adult kidney transplant recipients.

Authors:  Katherine A Barraclough; Nicole M Isbel; Carl M Kirkpatrick; Katie J Lee; Paul J Taylor; David W Johnson; Scott B Campbell; Diana R Leary; Christine E Staatz
Journal:  Br J Clin Pharmacol       Date:  2011-02       Impact factor: 4.335

2.  External evaluation of published population pharmacokinetic models of tacrolimus in adult renal transplant recipients.

Authors:  Chen-Yan Zhao; Zheng Jiao; Jun-Jun Mao; Xiao-Yan Qiu
Journal:  Br J Clin Pharmacol       Date:  2016-02-26       Impact factor: 4.335

3.  Population pharmacokinetic model and Bayesian estimator for two tacrolimus formulations--twice daily Prograf and once daily Advagraf.

Authors:  Jean-Baptiste Woillard; Brenda C M de Winter; Nassim Kamar; Pierre Marquet; Lionel Rostaing; Annick Rousseau
Journal:  Br J Clin Pharmacol       Date:  2011-03       Impact factor: 4.335

4.  The CYP3A biomarker 4β-hydroxycholesterol does not improve tacrolimus dose predictions early after kidney transplantation.

Authors:  Elisabet Størset; Kristine Hole; Karsten Midtvedt; Stein Bergan; Espen Molden; Anders Åsberg
Journal:  Br J Clin Pharmacol       Date:  2017-02-27       Impact factor: 4.335

Review 5.  Pharmacokinetic optimization of immunosuppressive therapy in thoracic transplantation: part I.

Authors:  Caroline Monchaud; Pierre Marquet
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

6.  Dosing equation for tacrolimus using genetic variants and clinical factors.

Authors:  Chaitali Passey; Angela K Birnbaum; Richard C Brundage; William S Oetting; Ajay K Israni; Pamala A Jacobson
Journal:  Br J Clin Pharmacol       Date:  2011-12       Impact factor: 4.335

7.  Population pharmacokinetic analysis of tacrolimus in Mexican paediatric renal transplant patients: role of CYP3A5 genotype and formulation.

Authors:  Carlos Orlando Jacobo-Cabral; Pilar García-Roca; Elba Margarita Romero-Tejeda; Herlinda Reyes; Mara Medeiros; Gilberto Castañeda-Hernández; Iñaki F Trocóniz
Journal:  Br J Clin Pharmacol       Date:  2015-06-22       Impact factor: 4.335

Review 8.  Drug interactions with tacrolimus.

Authors:  Teun van Gelder
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

9.  Tacrolimus population pharmacokinetic-pharmacogenetic analysis and Bayesian estimation in renal transplant recipients.

Authors:  Khaled Benkali; Aurelie Prémaud; Nicolas Picard; Jean-Philippe Rérolle; Olivier Toupance; Guillaume Hoizey; Alain Turcant; Florence Villemain; Yannick Le Meur; Pierre Marquet; Annick Rousseau
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 10.  Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation.

Authors:  Christine E Staatz; Susan E Tett
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.